Clinical trials on the efficacy and safety of citrus depressa seed extract extracted from citrus depressa seeds for motor function

Clinical trials for motor function of Nomilin - Clinical trials of Nomilin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046968

Enrollment

Registered

2022-02-22

Start date

2021-11-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decline in motor function with aging

Interventions

The test product is a capsule containing 80 mg of Shikuwasa seed extract (containing 65% nomilin and 25% limonin) and excipients. Evaluated for 8 weeks before, 4 and 8 weeks after ingestion. Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Men and women over the age of 65 who are basically healthy but feel some decline in motor function with aging

Exclusion criteria

Exclusion criteria: 1.Those who are being treated for motor dysfunction or taking supplements thereof 2.Those within half a year after the end of treatment for motor dysfunction 3.Those with disabilities in the limbs 4.Those who need long-term care to stand up or walk 5.Things that are difficult to communicate 6.Others that the doctor in charge judged inappropriate for registration in this study

Design outcomes

Primary

Measure	Time frame
Grip strength measurement, chair standing test, 6-minute walking test	—

Secondary

Measure	Time frame
Weight, body composition analysis	—

Countries

Japan

Contacts

Public ContactKimio Sugaya

Southern Knights' Laboratory Co., Ltd. CEO

sugaya@sklabo.co.jp090-4998-7459

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026